Follow @BiologyFool
Recent articles
Here's Why Reata Pharmaceuticals Skyrocketed Higher Today
Data from a phase 2 study looks promising.
Here's Why Stealth BioTherapeutics Rocketed Higher Today
The clinical-stage biotech made a new friend.
Here's Why Qiagen Plummeted Today
A trio of news items has the healthcare company in transition.
Here's Why Seattle Genetics Climbed 17.6% in September
Data from a pair of clinical trials sent shares of the oncology drugmaker higher.
Here’s Why Emergent BioSolutions Stock Climbed 19.4% in September
The bioterrorism expert finally completed its smallpox vaccine contract with the U.S. government.
Here's Why Alder Biopharmaceuticals More Than Doubled in September
A Denmark-based drugmaker thought the biotech was too cheap to pass up.
Here's Why Akcea Therapeutics Jumped 30% Today
A licensing deal gives investors confidence in a turnaround.
Here’s Why Acceleron Pharma Stock Fell 12% in September
The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
Here's Why Acadia Pharmaceuticals Jumped 30.1% in September
Unexpected phase 3 clinical trial data has investors smiling.
Winners and Losers of Europe’s Big Cancer Meeting
Unfortunately, there were more of the latter.
The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Here’s Why Seattle Genetics Stock Jumped Higher Today
Solid data for two pipeline candidates increases investors' confidence in the cancer biotech.
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
GLP-1 drugs keep getting easier to take.
The FDA Really Wants These Opioid Overdose Drugmakers to Succeed
In an unprecedented move, the agency is doing some of the legwork for the companies.
An Investor's Guide to Disrupting Drugmakers
Patents and monopolies don’t always go hand in hand.
Here’s Why Lexicon Pharmaceuticals Rose 18% Today
Investors are jumping in ahead of a data presentation tomorrow.
Here's Why Adverum's Shares Saw a Lower Price Today
The biotech’s gene therapy isn’t helping patients see better.
Here’s Why GW Pharmaceuticals Dropped 12% in August
The cannabis-focused biotech couldn’t hold its post-earnings gains.
Turns Out, It Wasn't Bad News for Intra-Cellular Therapies
Down over 18%, the biotech bounces back.
Here’s Why Align Technology Dropped 12.4% in August
Investors continue to worry about decelerating growth at the orthodontic-device specialist.